FDA grants accelerated approval for TRUTAKNA™ to treat IgA nephropathy

Vera Therapeutics announced that the FDA has granted accelerated approval for TRUTAKNA™ (atacicept-vymj) to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression. This approval allows the company to begin marketing and selling the drug based on the surrogate endpoint of proteinuria reduction while confirmatory clinical trials continue. For investors, this represents a pivotal commercial milestone that transitions Vera from a clinical-stage to a revenue-generating company.

The accelerated approval pathway enables earlier market entry for drugs addressing serious conditions where the surrogate endpoint is reasonably likely to predict clinical benefit. Vera can now begin generating product sales while completing the confirmatory studies required to maintain the approval.